Table 2.

Comparison of Different CINV Prophylactic Treatments in Randomized Pivotal Studies in AC-Based Regimes

Study and Study Arms	Number of Randomized Patients per Arm	Complete Response	No Significant Nausea
Warr et al Clin Oncol. 200542 APR+OND+DEX OND+DEX	438 428	Acute: 76% vs 69% * Delayed: 55% vs 49% Overall: 51% vs 42% *	Acute: not performed Delayed: not performed Overall: 61% vs 56%
Aapro et al Ann Oncol. 201426 NEPA+DEX PAL+DEX	724 725	Acute: 88.4% vs 85.0% * Delayed: 76.9% vs 69.5% * Overall: 74.3% vs 66.6% *	Acute: 87.3% vs 87.9% Delayed: 76.9% vs 71.3% * Overall: 74.6% vs 69.1% *
Schwartzberg et al Lancet Oncol. 201543 ROL+GRA+DEX GRA+DEX	344 359	Acute: 77% vs 77% Delayed: 67% vs 60% * Overall: 63% vs 55% *	Acute: not performed Delayed: not performed Overall: not performed

Note: *Results are statistically significant.

Abbreviations: CINV, chemotherapy-induced nausea and vomiting; AC, anthracycline-cyclophosphamide; APR, aprepitant; ROL, rolapitant; OND, ondansetron; GRA, granisetron; PAL, palonosetron; NEPA, netupitant + palonosetron; DEX, dexamethasone.